Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab.
Primary: To evaluate the safety and tolerability of FLX475 as a single agent and in combination with pembrolizumab in subjects with advanced cancer; To evaluate the anti-tumor activity of FLX475 as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors. Secondary: To define the maximum tolerated dose (MTD) and/or RP2D of FLX475, both as a single agent and in combination with pembrolizumab; To evaluate the PK profile of FLX475 alone and in combination with pembrolizumab; To assess the effects of FLX475 alone or in combination with pembrolizumab on PD markers relating to drug mechanism of action; To explore the relationships of PK and PD parameters to clinical drug activity; To characterize the onset, magnitude, and duration of tumor control in subjects receiving FLX475 alone or in combination with pembrolizumab
Immunotherapy; Therapy (NOS)
FLX475 (); Pembrolizumab (Keytruda)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.